ImagelockLocations / ImageScientists in the fermentation hub of Banting 1
Scientists in the fermentation hub of Banting 1.
ImagelockLocations / ImageScientist in a laboratory of Banting 1, office space in the background
Scientist in a laboratory of Banting 1, office space in the background.
lockDisease Awareness / Fact SheetSpinal Muscular Atrophy
Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.
lockScience & Innovation / Fact SheetThe Novartis AAV Platform
Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.
VideolockDisease Awareness / VideoScreen the Unseen: Newborn Screening for SMA
Early signs of spinal muscular atrophy can be subtle, and often go unseen by clinicians – which is why newborn screening is critical to help obtain a prompt diagnosis.
lockScience & Innovation / Fact SheetThe Novartis Gene Therapies Manufacturing Process
Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.
lockCorporate Responsibility / Fact SheetAbout Novartis Gene Therapies
Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.
VideolockScience & Innovation / VideoGene Therapy Manufacturing in North Carolina
A new, state-of-the-art gene therapy manufacturing facility in North Carolina, USA
lockScience & Innovation / Fact SheetAbout Gene Therapy
Gene therapy – an innovative approach to treating rare, genetic diseases.
ImagelockLeadership / ImageAharon (Ronny) Gal, Ph.D.
Chief Strategy & Growth Officer since July 18, 2022
lockNovartis Access / InfographicCrizanlizumab clinical setting from international managed access program (MAP)
Crizanlizumab clinical setting from international managed access program (MAP) infographic
ImagelockLeadership / ImageShreeram Aradhye, M.D.
President, Global Drug Development & Chief Medical Officer since May 16, 2022.